Master Knowledge Medical Center
USMLE/ MCCQE Preparation Courses in North America
About our USMLE/ MCCQE Preparation Courses :
We offer the best USMLE/ MCCQE preparation Courses both online and in-class courses, you can choose what suits your needs. We provide high-quality medical courses with a success rate of more than 97%. We have different kinds of courses; detailed courses and brief reviewing courses… However, we can help you to pick the course that fits your needs, depending on your medical knowledge and clinical skills, besides your past medical experiences.
Why should you pick our course over other programs offered?
The answer is simple because no one provides detailed interactive USMLE/ MCCQE Preparation Courses with high yield MCQs/ Cases like us… This is not our opinion but that’s our students’ impressions.
What is our course strategy?
Our unique USMLE/ MCCQE preparation Courses strategy is to organize and build your information from zero to high-level end throughout an interactive manner supported by medical animation videos, images, and diagrams. You can find more details about them here.
Exams Success Rate
Mk Medical Center offers the highest quality USMLE/ MCCQE preparation Courses on the market. Their expert Physicians’ team provides you with high-yield, most relevant recourses and up-to-date curriculum materials and clinical approaches to help you prepare for MCCQE exams in order to pass them with the highest score that you can achieve.
They have thousands of hours of medical education experience.
According to our latest IMGs passing exams survey, we still have a high success rate up to 96%.
MK Medical Group
Press & News
The SARS-CoV-2 omicron variant, first detected in South Africa on 24 November, has now been found in 57 countries. Elisabeth Mahase looks at what we know about it so far, including how well treatments and vaccines workWhat mutations does omicron have?Omicron’s spike protein has at least 30 amino acid substitutions, three small deletions, and one small insertion, […]
Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well as with other type 2 inflammatory diseases.In this 52-week phase 3, randomized, double-blind, placebo-controlled trial, we assigned 408 children between the ages […]